Skip to main content

Current licensing opportunities

Current licensing opportunities

Licensing opportunities for Royal Holloway research.

There are a number of current licensing opportunities available for Royal Holloway research, based on patent applications or granted patents.

The Artibody technology represents a radically different method of designing protein affinity reagents.

Artibodies are polypeptides which bind target proteins by displacing surface exposed elements of the target proteins.

With Artibody technology, some of the surface exposed mobile elements of the protein structure can be displaced by polypeptides with similar or identical sequences. These sequences fit the target protein perfectly, taking advantage of the inherent flexibility in protein structures.

Competitive advantages of the Artibody technology:

  • easy to design Artibody molecules based on the target protein structure or sequence
  • no need to immunise animals, no need to screen huge libraries of recombinant antibodies
  • short polypeptides are easy and cheap to manufacture by chemical synthesis
  • no need for recombinant production, better reproducibility, fewer quality control issues
  • unaffected by denaturing reagents, increased stability compared to immunoglobulins or other protein based affinity reagents
  • smaller size and increased stability makes Artibodies attractive therapeutic drug candidates

We are now looking for partnering opportunities for licensing, consultancy or contract research of PCT patent application no. PCT/GB2010/050838.

For further information contact Joanna Cox, Business Development Manager, BioSciences:

01784 414969


Work by scientists at Royal Holloway has identified novel therapies for neurological disorders based around the actions of Valproic acid (VPA).

VPA is widely used for the treatment of epilepsy, bipolar disorder and migraine, but its action is poorly understood.

Our scientists used a simple biomedical model to determine several biochemical mechanisms and identify related compounds with substantially higher potency for these effects.

When tested in vitro and in vivo the compounds caused up to a three-fold increase in animal epilepsy seizure protection. We have now patented a range of novel compounds related to the structure of VPA, which we anticipate will show increased efficacy and reduced side-effects in comparison with the parent compound.

We are now looking for commercial partners to develop this further.

For further information contact Joanna Cox, Business Development Manager, BioSciences:

01784 414969


Making use of unusual materials and a novel geometry, scientists from Royal Holloway have fabricated a Quantum non-demolition interference device for ultralow noise ultrasensitive vector magnetometry and as a read out of superconducting quantum circuits.

The device is much more sensitive (*3000) than a conventional SQUID because it does not need an electrical connection to achieve a measurement.

With no introduced noise, measurements can be taken much faster - minutes rather than days. Also, there is no back action so quantum bits can be measured.

The new device is based on the Andreev probe. A number of modifications were carried out to make the probe a complete quantum nondemolition (QND) interference device.

For further information contact Martin Kelly, Head of Research  and Business Development:

01784 414968

The RFID Attack Detector (RAD) is an intelligent sniffer (radio receiver) designed to detect attempted attacks on RFID, contactless smart card and NFC-based systems in real time.

The Information Security Group Smart Card Centre has been carrying out research and providing expert advice on detecting attacks on contactless/smartcard systems for several years.

The RAD incorporates this research and expertise into a practical device that can detect unusual physical activity by the device, for example deviations from expected radio frequency or timing behaviour. It can also detect variations from expected interaction protocols, which may be attempts to explore the RFID system protocols and/or obtain cryptographic keys.

The RAD is applicable to many areas where contactless technology is increasingly important and is under continuous scrutiny from hackers.

A working prototype has been built with a realistic form factor for practical deployment and has been successfully demonstrated to RFID technology user organisations.

We are now seeking partners to license or jointly develop the technology, international Patent Application No. PCT/GB2010/000167.

For further information contact David Wells, Business Development Manager, ICT: +44 (0)1784 414931

Explore Royal Holloway

Get help paying for your studies at Royal Holloway through a range of scholarships and bursaries.

There are lots of exciting ways to get involved at Royal Holloway. Discover new interests and enjoy existing ones

Heading to university is exciting. Finding the right place to live will get you off to a good start

Whether you need support with your health or practical advice on budgeting or finding part-time work, we can help

Discover more about our 21 departments and schools

Find out why Royal Holloway is in the top 25% of UK universities for research rated ‘world-leading’ or ‘internationally excellent’

Royal Holloway is a research intensive university and our academics collaborate across disciplines to achieve excellence.

Discover world-class research at Royal Holloway

Discover more about who we are today, and our vision for the future

Royal Holloway began as two pioneering colleges for the education of women in the 19th century, and their spirit lives on today

We’ve played a role in thousands of careers, some of them particularly remarkable

Find about our decision-making processes and the people who lead and manage Royal Holloway today